Citations

Clear

16280 citation(s) found for "Yu, David".

Long-Term Patient-Reported Bowel and Urinary Quality of Life in Patients Treated with Intensity-Modulated Radiotherapy Versus Intensity-Modulated Proton Therapy for Localized Prostate Cancer
Gergelis, Kimberly R. , Bai, Miao , Ma, Jiasen , Stish, Bradley J. , Davis, Brian J. , Pisansky, Thomas M. , Whitaker, Thomas J. , Choo, Richard , Davis, Brian J , Bai, Miao , Routman, David M.

Mayo Clinic

Current Oncology | April 2, 2025 | Volume: 32 | Issue: 4 | Pages: 212

10.3390/curroncol32040212 | PMID 40277768 Get It

Purpose: This study aimed to compare long-term patient-reported outcomes in bowel and urinary domains between intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT) for localized prostate cancer. Methods and Materials: Patients with clinical T1–T2 prostate cancer receiving IMRT or IMPT at a tertiary cancer center from 2015–2018 were analyzed to determine the changes in the prospectively collected bowel function (BF), urinary irritative/obstructive symptoms (UO), and urinary incontinence (UI) domains of EPIC-26. The mean changes in EPIC-26 scores were evaluated from pretreatment to 24 months post-radiotherapy for each modality. A score change >50% of the baseline standard deviation was considered a clinically meaningful change. Results: A total of 82 patients treated with IMRT (52.2%) and 56 patients treated with IMPT (53.3%) completed the questionnaire at baseline and 24 months post-RT. There were no baseline differences in domain scores between treatment modalities. At 24 months post-radiotherapy, there was a significant and clinically meaningful decline in the BF mean score in the IMRT cohort (−4.52 (range −50, 29.17), p = 0.003), whereas the decline in BF score did not reach clinical relevance or significance (−1.88 (range −37.5, 50), p = 0.046) when accounting for the Bonferroni adjustment in the IMPT cohort. A higher proportion of patients treated with IMRT had a clinically relevant reduction in BF when compared with IMPT (47.37% vs. 25.93%, p = 0.017). The mean changes in the UI and UO scores of the IMRT and IMPT cohorts were neither statically significant nor clinically relevant. Conclusions: IMPT leads to a smaller decrease in BF than IMRT at 24 months post-RT, while there was no differential effect on UO and UI.
Time to complete oncology pharmacist tasks: A joint opinion of the Hematology/Oncology Pharmacy Association and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network
Griffin, Shawn P. , Signorelli, Jessie , Raheem, Farah , Adler, Kristin, Benitez, Lydia L. , Cheng, Rose, Dotson, Emily, Fares, Marielle, Ganti, Beejal R., Hickey, Erin , Lasko, Aubrey , Lewallen, Amanda B , Lynch, Alia, Paulic, Nikola, Quach, David, Vogel, Vishnuprabha, Yacobucci, Matthew J , Riebandt, Grazyna, Lasko, Aubrey R , Yacobucci, Matt , Adler, Kristin, Lewallen, Amanda

Mayo Clinic

Journal of Oncology Pharmacy Practice | April 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10781552251330252 | PMID 40170460 Get It

Purpose The time to complete oncology pharmacist tasks is needed to determine workload and productivity. The Hematology/Oncology Pharmacy Association (HOPA) and the Hematology/Oncology Practice and Research Network (PRN) of the American College of Clinical Pharmacy (ACCP) partnered with the aim of establishing consensus on the time required to complete oncology pharmacy tasks. Methods Fifteen patient care tasks and 9 non-patient care tasks, commonly completed by oncology pharmacists were each assigned an average amount of time to be completed. This list was then converted into 24 statements and the Delphi survey method was utilized with an expert panel to arrive at consensus between December 2023 and February 2024. Consensus was defined as at least 75% agreement. The complete manuscript was endorsed by HOPA and ACCP Hematology/Oncology PRN. Results Thirty-three pharmacist-experts agreed to participate in this survey with all participating in round 1, and 29 (87.9%) participating in round 2. In round 1, 9 tasks achieved consensus, with 7 of these being classified as patient care associated. Seven statements reaching 65% but less than 75% agreement were deemed to reach borderline consensus. Eight statements failed to achieve at least 65% agreement and were modified based on respondent feedback. In round 2, 15 statements were included with all achieving consensus. At the completion of round 2, all 24 statements reached consensus, and the survey was deemed complete. Conclusion This project produced the first comprehensive consensus statements for the average time for a US-based oncology pharmacist to complete common patient and non-patient care-related tasks.
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial
Singh, Siddharth , Nguyen, J. , Fudman, David , Gerich, Mark E. , Hudesman, David , McConnell, Ryan , Flynn, Ann D. , Hwang, Caroline, Sprung, Brandon, Gaidos, Jill , Mattar, Mark , Metwally, Mark, Ali, Tauseef , Narula, Neeraj, Rosenfeld, Greg , Cross, Raymond, Gaytán, Josep María, Gurrola, Emily-Sophinie, Patel, Sagar , Melmed, Gil , Weaver, Sarah , Power, Sydney, Jairath, Vipul , Hou, Jason K. , Jairath, Vipul , Jairath, Vipul , Fudman, David I , Hudesman, David , Flynn, Ann D , Sprung, Brandon , Gaidos, Jill K J , Ali, Tauseef , Hoentjen, Frank , Bessissow, Talat , Patel, Sagar , Siegel, Corey A , Zou, Guangyong , Jairath, Vipul , Jairath, V , Jairath, V , Melmed, Gil Y , Nguyen, Jasmine D, Shah, Shiraz Ali , Lukin, Dana J. , Rubin, David T. , Hashash, Jana G. , Ma, C , Narula, Neeraj , Bessissow, Talat , McCurdy, Jeffrey D , Ananthakrishnan, Ashwin N. , Gurrola, Emily-Sophinie, Power, Sydney , Zou, Guangyong

Mayo Clinic

BMJ Open Gastroenterology | April 1, 2025 | Volume: 12 | Issue: 1 | Pages: e001615

10.1136/bmjgast-2024-001615 | PMID 40164445 Get It

Introduction Targeted immunomodulators (eg, advanced therapies) effectively achieve symptomatic remission in patients with inflammatory bowel disease (IBD). However, ~25%–50% of patients with IBD achieving symptomatic remission with an advanced therapy may have continued endoscopically/radiologically active bowel inflammation, and it is uncertain whether changing alternative advanced therapies in asymptomatic patients with IBD will reduce bowel inflammation and achieve durable deep remission. Methods and analysis The QUality Outcomes Treating IBD to Target (QUOTIENT) study is an open-label, multicentre, pragmatic, randomised, controlled trial that aims to compare the efficacy and safety of switching to an alternative advanced therapy targeting endoscopic/radiological remission (treat-to-target) versus continuing the initial, or index, advanced therapy, in asymptomatic patients with IBD with moderate-to-severe endoscopic/radiological bowel inflammation. Enrolment is planned for ~250 participants in Canada/USA, randomised 1:1 to switching to alternative advanced therapy or continuing index advanced therapy, and then followed 104 weeks within routine clinical practice. Patient-reported outcomes measure efficacy and quality of life/treatment burden/safety. Primary endpoint is the time from randomisation to treatment failure. Ethics and dissemination The study is conducted in compliance with the protocol, ICH Good Clinical Practice, applicable regulatory requirements and appropriate review boards/independent ethics committees (approval numbers: Pro00077486; Pro00061437; STUDY00002062; 22-004171; i22-01269; IRB22-0890; IRB_00154397; 2000032384; SHIRB#2022.095-2; STUDY00007146; MMC#2024-18; REB#125290; 17784; Pro00142214; 20240660-01H), with documented written informed consent. Findings will be disseminated through peer-reviewed journals, scientific presentations, and publicly available Patient-Centered Outcomes Research Institute (PCORI) websites, including lay summaries. The Crohn’s & Colitis Foundation Education, Support, and Advocacy Department, and our patient advocacy stakeholder, will develop educational and marketing resources to communicate findings to a broad audience (>250 000 patients/caregivers/healthcare professionals). Trial registration number NCT05230173 .
A Qualitative Study of the Effects of Opioids on Chronic Pain, Function, and Cognition in Community-Dwelling Older Adults
Warner, Nafisseh S. , Finnie, Dawn M., Smith, Jamie, Verdoorn, Brandon P. , Tung, Ericka E. , Griffin, Joan M. , Griffin, Joan M , Warner, Nafisseh , Smith, Jamie L , Warner, David O. , Mielke, Michelle M.

Mayo Clinic

Journal of Applied Gerontology | April 1, 2025 | Volume: 44 | Issue: 12 | Pages: 1939-1949

10.1177/07334648251326347 | PMID 40167777 Get It

Chronic pain is common with aging. Yet, little is known about the attitudes, beliefs, and experiences of older adults with chronic pain regarding opioids, particularly in regard to effects on daily functioning and cognition. This qualitative analysis employed semi-structured interviews in 25 community-dwelling older adults with chronic pain and current or recent prescription opioid use. Interviews focused on perceptions, beliefs, and experiences of living with chronic pain, use of prescription opioids, and the impact of opioids on pain control, cognition, and daily function. Older adults display adaptability and acceptance in living with chronic pain, desire person-centered pain care, approach the risks-benefits of opioids with regards to cognition differently, and perceive stigma as a barrier to effective partnership with clinicians.
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis
Reinisch, Walter , Loftus, Edward V. , Schreiber, Stefan, Rubin, David T. , Louis, Edouard, Hecht, Patrick , Barrachina, Elena Marced, Kalabic, Jasmina , Vladea, Ramona, Sharma, Dolly, Duan, W. Rachel, Zhang, Yafei , Panaccione, Remo , Loftus, Edward V , Rubin, David T , Reinisch, Walter , Panaccione, Remo

Mayo Clinic

Journal of Crohn's and Colitis | April 1, 2025 | Volume: 19 | Issue: 4 | Pages: No page available

10.1093/ecco-jcc/jjaf025 | PMID 40168091 Get It

Abstract Background and aims This post hoc analysis evaluated the corticosteroid-sparing effects of risankizumab (RZB) therapy in patients with moderate-to-severe ulcerative colitis in the phase 3 induction and maintenance studies, INSPIRE and COMMAND. Methods Patients were randomized (2:1) to 12 weeks of intravenous RZB or placebo (PBO) induction therapy; responders to intravenous RZB were randomized (1:1:1) to receive subcutaneous RZB 180 mg, 360 mg, or PBO (RZB withdrawal) maintenance therapy. Baseline corticosteroid doses were maintained during induction, with a mandatory taper beginning at maintenance week 0. Efficacy outcomes were evaluated by baseline corticosteroid use at induction week 12, while corticosteroid-free clinical and endoscopic outcomes were assessed at maintenance week 52 among the overall population and among patients on corticosteroids at baseline. Safety was also assessed. Results At baseline, 35.7% (348/975) of patients were taking corticosteroids. At induction week 12, greater rates were observed for clinical, endoscopic, and patient-reported outcomes in RZB 1200 mg-treated patients compared with PBO, regardless of baseline corticosteroid use. RZB 180 mg and 360 mg treatment resulted in higher corticosteroid discontinuation rates (RZB 180 mg 64.9% [48/74]; RZB 360 mg 54.2% [32/59]; PBO [withdrawal] 36.8% [25/68], P ≤ .01) and corticosteroid-free clinical, endoscopic, and patient-reported outcomes at week 52, compared with PBO (withdrawal). The rates of treatment-emergent adverse events were similar regardless of baseline corticosteroid use during induction and maintenance. Conclusions The efficacy of RZB induction therapy was independent of corticosteroid use, with high rates of corticosteroid-free outcomes observed in the overall population and among patients with baseline corticosteroid use, reaffirming the potential of RZB to serve as a corticosteroid-sparing therapy for patients with ulcerative colitis. Clinicaltrial.gov numbers NCT03398148 and NCT03398135
Peripheral Spondyloarthritis: Conceptualization and Diagnosis as a Distinct Rheumatologic Subset of Disease
Chroneos, Paul, Melville, David M. , Long, Jeremiah R. , Flug, Jonathan A. , Melville, David, Flug, Jonathan A , Nagaraja, Vivek

Mayo Clinic

Seminars in Musculoskeletal Radiology | March 31, 2025 | Volume: 29 | Issue: 02 | Pages: 236-248

10.1055/s-0045-1802350 | PMID 40164080 Get It

AbstractPeripheral spondyloarthritis (pSpA) encompasses multiple entities affecting the musculoskeletal system with classic findings of synovitis, enthesitis, and tenosynovitis. It remains poorly defined when compared with the axial spondyloarthritides due to nonspecific symptoms, ill-defined imaging findings, and lack of specific testable biomarkers. Previous research has tried to distinguish between the two disease entities using clinical presentations, scoring systems, and radiographic findings; however, overlap remains. We summarize the current classification of pSpA, imaging findings, and the distinction between these entities and axial spondyloarthritis.
State of the Art of Artificial Intelligence in Clinical Electrophysiology in 2025: A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), and the ESC Working Group on E-Cardiology
Svennberg, Emma , Han, Janet K. , Caiani, Enrico G. , Engelhardt, Sandy , Friedman, Paul A. , Garcia, Rodrigue , Ghanbari, Hamid , Hindricks, Gerhard , Man, Sharon , Hansen, Jacob Tfelt, Barker, Joseph, Casado-Arroyo, Ruben, Chatterjee, Neal A, Conte, Giulio, Diederichsen, Søren Zöga, Linz, Dominik, Mahtani, Arun Umesh, Zorzi, Alessandro, Tfelt‐Hansen, Jacob , Diederichsen, Søren Zöga , Ernst, Sabine , Friedman, Paul A , Garcia, Rodrigue , Hindricks, Gerhard , Man, Sharon H , Millet, José , Narayan, Sanjiv M , Ng, G. André , Noseworthy, Peter A , Tjong, Fleur V Y , Ramírez, Julia , Singh, Jagmeet P , Trayanova, Natalia A , Duncker, David , Tfelt-Hansen, Jacob , Diederichsen, Søren Z , Ernst, Sabine , Narayan, Sanjiv M. , Noseworthy, Peter A. , Ramírez, Julia , Trayanova, Natalia A. , Duncker, David , Barker, Joseph, Casado-Arroyo, Ruben, Chatterjee, Neal A, Conte, Giulio, Linz, Dominik, Mahtani, Arun Umesh, Zorzi, Alessandro

Mayo Clinic

Europace | March 31, 2025 | Volume: 27 | Issue: 5 | Pages: No page available

10.1093/europace/euaf071 | PMID 40163651 Get It

Abstract Aims Artificial intelligence (AI) has the potential to transform cardiac electrophysiology (EP), particularly in arrhythmia detection, procedural optimization, and patient outcome prediction. However, a standardized approach to reporting and understanding AI-related research in EP is lacking. This scientific statement aims to develop and apply a checklist for AI-related research reporting in EP to enhance transparency, reproducibility, and understandability in the field. Methods and results An AI checklist specific to EP was developed with expert input from the writing group and voted on using a modified Delphi process, leading to the development of a 29-item checklist. The checklist was subsequently applied to assess reporting practices to identify areas where improvements could be made and provide an overview of the state of the art in AI-related EP research in three domains from May 2021 until May 2024: atrial fibrillation (AF) management, sudden cardiac death (SCD), and EP lab applications. The EHRA AI checklist was applied to 31 studies in AF management, 18 studies in SCD, and 6 studies in EP lab applications. Results differed between the different domains, but in no domain reporting of a specific item exceeded 55% of included papers. Key areas such as trial registration, participant details, data handling, and training performance were underreported (<20%). The checklist application highlighted areas where reporting practices could be improved to promote clearer, more comprehensive AI research in EP. Conclusion The EHRA AI checklist provides a structured framework for reporting AI research in EP. Its use can improve understanding but also enhance the reproducibility and transparency of AI studies, fostering more robust and reliable integration of AI into clinical EP practice.
Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial
Desai, Milind Y. , Owens, Anjali , Saberi, Sara , Wang, Andrew , Wolski, Kathy, Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Zenker, Mark, Geske, Jeffrey B. , Naidu, Srihari S. , Lampl, Kathy, Nissen, Steven E. , Investigators, for the VALOR-HCM, Wolski, Kathy , Cremer, Paul C , Tower-Rader, Albree , Sherrid, Mark , Geske, Jeffrey B , Fermin, David , Naidu, Srihari S , Nissen, Steven E , Saberi, Sara , Wang, Andrew , Zenker, Mark, Sherrid, Mark V. , Fermin, David , Investigators, for the VALOR-HCM

Mayo Clinic

Circulation: Genomic and Precision Medicine | March 31, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circgen.125.005100 | PMID 40163785 Get It

Overall and Cause-Specific Mortality in Patients With Barrett's Esophagus: A Systematic Review and Meta-Analysis of Population-Based Studies
Sawas, Tarek , Jones, Alex R. , Alsawas, Rand, Talluri, Rachna , Rogers, Hayley , Spezia-Lindner, David, Gerberi, Dana , Singh, Siddharth , Shaheen, Nicholas J. , Katzka, David A. , Wani, Sachin , Bardhi, Olgert , Gerberi, Danielle J , Bardhi, Olgert , Spezia-Lindner, David Ethan, Murad, M. Hassan

Mayo Clinic

American Journal of Gastroenterology | March 31, 2025 | Volume: 121 | Issue: 1 | Pages: 140-150

10.14309/ajg.0000000000003456 | PMID 40162666 Get It

INTRODUCTION: Current guidelines recommend endoscopic surveillance of Barrett's esophagus (BE) but do not account for competing mortality unrelated to esophageal cancer (EC). We conducted a systematic review and meta-analysis to estimate EC and non-EC mortality risk in BE patients. METHODS: We searched multiple databases for studies reporting mortality in BE. We included population-based studies providing standardized mortality ratio (SMR). The primary outcome was SMR from all causes and EC and non-EC etiologies. SMR was calculated by dividing the observed mortality over the expected mortality. Logarithmic form of SMRs was pooled using random-effects model. RESULTS: Our search yielded 2,826 articles, of which 7 studies (n = 34,454) were included. All-cause mortality was elevated in BE patients compared with population controls (pooled SMR 1.24, 95% confident interval [CI] 1.01–1.53) driven in part by increased EC mortality risk (SMR 8.98, 95 CI 5.12–15.77). The mortality risk was still increased but attenuated after excluding EC mortality (SMR 1.21, 95% CI 1–1.46). There was no increased mortality risk of non-EC malignancies (SMR 1.22, 95% CI 0.82–1.82) or mortality due to noncancer etiologies (SMR 1.13, 95% CI 0.90–1.43). Death due to cardiovascular diseases was higher in BE (SMR 1.16, 95% CI 1.02–1.33). BE patients were 10 times more likely to die from noncancer etiologies than EC (risk ratio 10.71, 95% CI 5.98–19.16). Subgroup analysis of studies that excluded prevalent EC at baseline (3 studies) also showed increased all-cause (SMR 1.12, 95% CI 1.07–1.18) and EC mortality (SMR 4.7, 95% CI 3.58–6.17) among BE patients. DISCUSSION: BE patients exhibit a higher all-cause mortality, driven in part by risk of EC mortality. A personalized approach to surveillance, mitigating risk of EC while recognizing the broader mortality risks, is warranted.